Cerenome (fka Plus Therapeutics) reports Q2 2026 net loss $9.0M, rebrands to CNSY

PLUS THERAPEUTICS, INC.

Q2 2026 net loss $9.0M ($1.31/sh) vs net income $5.2M ($0.62/sh) in Q2 2025, which included $6.5M derivative gain.
Operating loss widened to $9.1M from $1.5M; grant revenue fell to $0.4M from $1.4M; cash flat at $8.6M.
Rebranded from Plus Therapeutics to Cerenome on Aug 3, 2026; now trades as CNSY on Nasdaq.
ReSPECT-GBM Phase 2 enrollment on track for 2026; data expected Q1 2027; ReSPECT-PBC first dosing Q3 2026.
CNSide performed 232 tests in H1 2026; achieved 150M covered lives, CAP accreditation, and new partnerships.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.